- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00489645
Effect of Hyperglycemia on Gastric Emptying Interactions With Pramlintide
The Influence of Ambient Glycemia on the Effect of Pramlintide on Gastric Emptying in Patients With Type 1 Diabetes and Healthy Subjects
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Postprandial increases in plasma glucose concentrations are mainly determined by the degree of postprandial suppression of endogenous glucose production and the rate of appearance of the ingested glucose. The latter is predominantly determined by the amount of glucose taken up by the splanchnic bed. Because nutrient absorption depends on gastric nutrient delivery, gastric emptying rate is a key determinant of the early rise of plasma glucose postprandially. At mealtime, the faster the stomach empties the more rapid the rise in plasma glucose. Yet, plasma glucose concentration is a determinant of gastric emptying rate. In non-diabetic subjects, as plasma glucose rises and approaches the upper limit of the normal range (~140 mg/dl), gastric emptying slows. This likely represents a physiological brake mechanism to limit excess delivery of nutrients, thus avoiding excessive appearance of glucose in plasma. In diabetes, abnormally accelerated gastric emptying as well as delayed gastric emptying have been reported. These conflicting data may be explained by differences of ambient glycaemia. In most of these studies undertaken in diabetic subjects these patients were severely hyperglycaemic, thus the reported delayed gastric emptying may be explained by the effect of hyperglycaemia on gastric motility. Indeed, a small number of studies controlled for ambient glycaemia found acceleration of gastric emptying in diabetes and suggest that diabetes manifests with a maladaptive acceleration of gastric emptying likely contributing to excessive postprandial plasma glucose excursions.
The amylin analog pramlintide is a potential new therapeutic that elicits a potent glucose lowering effect in the postprandial period thought to be due to both a suppression of plasma glucagon and a delay of gastric emptying. It is not clear, however, to what extent the pramlintide-induced delay of gastric emptying offsets a potential maladaptive acceleration of gastric emptying in diabetes patients studied under controlled glycemic conditions. In theory, every drug that reduces hyperglycaemia should accelerate gastric emptying and, thereby, minimize its potential effect on postprandial hyperglycaemia. Thus, the drug-induced effect of amylin on gastric motility may be of great advantage by offset the effects of glycemic induced acceleration on gastric emptying.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
All of the following criteria are to be fulfilled for inclusion of an individual in the study unless the investigator grants an exception:
- Clinical diagnosis of type 1 diabetes (otherwise healthy) with an HbA1 ≤ 9%, and on a stable insulin treatment for at least 3 months (preferably on pump regimen) prior to screening OR is a healthy individual.
- 20-40 years of age, inclusive.
- Understand and sign an informed consent document, communicate with the investigator, and understand and comply with the requirements of the study.
- Euthyroid, including subjects receiving thyroid replacement therapy.
If female:
- Is surgically sterilized by hysterectomy; OR
- Is post-menopausal, as documented by a history of amenorrhea for 6 months and follicle stimulating hormone (FSH) level within the range specified as post-menopausal by the reporting laboratory at screen (post menopausal women on estrogen may enter the study without obtaining an FSH level); OR
- If of childbearing potential, meets the following criteria:
negative pregnancy test (ß-HCG), regardless of birth control method (including subjects with tubal ligation);
- Practicing and willing to continue throughout the study the appropriate contraception (defined as oral, injected, or implanted contraceptives for at least 3 months prior to entry, or barrier contraception).
- Agree to take every precaution to ensure that pregnancy will not occur during the study.
Exclusion Criteria:
- Individuals meeting any of the following criteria are to be excluded from the study unless the investigator grants an exception:
- History of severe hypoglycemia.
- Body mass index (BMI) ≥ 30 kg/m2.
- Autonomic nerve dysfunction: abnormal result in the cardiovascular parasympathetic and/or sympathetic tests (screening visit).
Hepatic disease:
- Known hepatic disease or transaminases (GOT, GPT) ≥ 2x above normal values.
Renal disease:
- Known or serum urea, serum creatinine ≥ 1.5x above normal values
- Cardiovascular or pulmonary disease:
- Arterial hypertension
- Blood pressure >150/95 mmHg at screening in a sitting position)
- Arterial occlusive disease
- Known coronary heart disease
- Abnormal ECG at screening visit.
- Gastrointestinal disease:
- Any known structural gastrointestinal disorder,
- Gastrointestinal surgery except for appendectomy,
- Symptoms indicating functional or structural upper gastrointestinal disorder (pain, bloating, postprandial fullness, nausea, emesis,
- Gastroectomy, gastroparesis, lactose intolerance, and diseases known to alter small bowel absorption; e.g., inflammatory bowel disease.
CNS disease:
- Epilepsy (including subjects with a past history of convulsions associated with hypoglycaemia),
- Psychiatric illness (including history of eating disorder such as bulimia or anorexia).
- Autoimmune disease other than thyroid, pernicious anemia, or vitiligo.
- Malignant disease requiring chemotherapy,
- Any acute febrile illness within 2 weeks of Screening (Visit 1) with a temperature of 100°F,
- Currently abusing alcohol or drugs, or have a history of alcohol or drug abuse that in the investigator's opinion could cause the subject to be non-compliant; or have a general history of non-compliance with medications.
- Receipt of any investigational drug within 90 days of Screening (Visit 1) (prior treatment with pramlintide is permissible).
Currently treated with medications known to interfere with gastric emptying such as, but not limited to:
- Ca2+ channel antagonists, ß-receptor antagonists, prokinetic agents metoclopramide (Reglan®) and cisapride (Propulsid®); and
- Chronic (more than 10 days within a 6-month period) macrolide antibiotics such as erythromycin and newer derivatives.
Currently treated with:
- Bile acid sequestering resins cholestyramine (Questran®) and colestipol (Colestid®),
- Systemic steroids,
- Anti-obesity agents (including orlistat [Xenical®] and sibutramine [Meridia®]),
- Alpha-glucosidase inhibitors (acarbose [Precose®] and miglitol [Glyset®]) and meglitinides ([Prandin®] and [Starlix®]).
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Diagnose
- Zuteilung: Zufällig
- Interventionsmodell: Crossover-Aufgabe
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Placebo-Komparator: 1
Placebo, euglycemia
|
placebo SC during euglycemia
placebo during hyperglycemia
|
Experimental: 2
Pramlintide, euglycemia
|
pramlintide SC during eglycemia
pramlintide SC during hyperglycemia
|
Placebo-Komparator: 3
placebo, hyperglycemia
|
placebo SC during euglycemia
placebo during hyperglycemia
|
Experimental: 4
pramlintide, hyperglycemia
|
pramlintide SC during eglycemia
pramlintide SC during hyperglycemia
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
• To examine the influence of acute glycaemia (normoglycaemia and hyperglycaemia) on gastric emptying kinetics in patients with type 1 diabetes and non diabetic subjects when treated with subcutaneous (SC) injections of pramlintide.
Zeitfenster: 2 years
|
2 years
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
• Gastric peristalsis derived from high-resolution scintigraphy by means of Fast Fourier Transform (FFT) analysis. • Effects on gastric emptying and on the rate of appearance of ingested glucose appearance, postprandial glucose sequestration, endoge
Zeitfenster: 2 years
|
2 years
|
Mitarbeiter und Ermittler
Mitarbeiter
Ermittler
- Hauptermittler: Joerg Schirra, MD, Ludwig-Maximilians-University of Munic
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Störungen des Glukosestoffwechsels
- Stoffwechselerkrankungen
- Erkrankungen des Immunsystems
- Autoimmunerkrankungen
- Erkrankungen des endokrinen Systems
- Diabetes Mellitus
- Diabetes mellitus, Typ 1
- Hypoglykämische Mittel
- Physiologische Wirkungen von Arzneimitteln
- Molekulare Mechanismen der pharmakologischen Wirkung
- Appetitzügler
- Mittel gegen Fettleibigkeit
- Amylin-Rezeptor-Agonisten
- Pramlintide
- Insel-Amyloid-Polypeptid
Andere Studien-ID-Nummern
- PRAM025/04
- DFG Schi 527/1-2
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Diabetes Typ 1
-
Eledon PharmaceuticalsZurückgezogenSpröder Diabetes mellitus Typ 1Vereinigte Staaten
-
Shanghai Jiao Tong University School of MedicineRekrutierung
-
Hadassah Medical OrganizationUnbekanntUnkontrollierte Typ-1-Diabetiker
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)AbgeschlossenDiabetes mellitus Typ 1 | T1DM | T1D | Neu aufgetretener Diabetes mellitus Typ 1Vereinigte Staaten, Australien
-
Shanghai Changzheng HospitalRekrutierungSpröder Diabetes mellitus Typ 1China
-
Capillary Biomedical, Inc.AbgeschlossenDiabetes mellitus, Typ 1 | Diabetes Typ 1 | Diabetes mellitus Typ 1 | Diabetes mellitus, insulinabhängig, 1Australien
-
Spiden AGDCB Research AGRekrutierungDiabetes mellitus Typ 1 | Diabetes mellitus Typ 1 mit Hypoglykämie | Diabetes mellitus Typ 1 mit HyperglykämieSchweiz
-
Capillary Biomedical, Inc.BeendetDiabetes Typ 1 | Diabetes mellitus Typ 1 | Diabetes mellitus, Typ I | Diabetes mellitus, insulinabhängig, 1 | IDDMÖsterreich
-
Instytut Diabetologii Sp. z o.o.National Center for Research and Development, Poland; Nalecz Institute of Biocybernetics...UnbekanntDiabetes mellitus Typ 1 mit Hyperglykämie | Diabetes mellitus Typ 1 mit HypoglykämiePolen
-
Poznan University of Medical SciencesUnbekanntDiabetes mellitus Typ 1 | Remission von Typ-1-Diabetes | Chronische Komplikationen von DiabetesPolen
Klinische Studien zur placebo
-
SamA Pharmaceutical Co., LtdUnbekanntAkute Bronchitis | Akute Infektion der oberen AtemwegeKorea, Republik von
-
National Institute on Drug Abuse (NIDA)AbgeschlossenCannabiskonsumVereinigte Staaten
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyAbgeschlossenMännliche Probanden mit Typ-II-Diabetes (T2DM)Deutschland
-
Texas A&M UniversityNutraboltAbgeschlossenGlucose and Insulin Response
-
Instituto de Investigación Hospital Universitario...Creaciones Aromáticas Industriales, S.A. (CARINSA)Abgeschlossen
-
Soroka University Medical CenterAbgeschlossen
-
Regado Biosciences, Inc.AbgeschlossenGesunder FreiwilligerVereinigte Staaten
-
ItalfarmacoAbgeschlossenBecker-MuskeldystrophieNiederlande, Italien
-
Longeveron Inc.BeendetHypoplastisches LinksherzsyndromVereinigte Staaten